Guardant Health's Guardant360 TissueNext test has received Medicare coverage under an existing local coverage determination by Medicare administrative contractor Palmetto GBA.
The new policy covers Guardant360 TissueNext as a standalone service for Medicare fee-for-service patients with advanced solid-tumor cancers. Guardant360 TissueNext -- the firm's first tissue-based test -- can assist oncologists in identifying cancer patients who may benefit from biomarker-informed treatment, Guardant said.
